Self-renewal is the hallmark feature both of normal stem cells and cancer stem cells 1 . Since the regenerative capacity of normal haematopoietic stem cells is limited by the accumulation of reactive oxygen species and DNA double-strand breaks [2] [3] [4] , we speculated that DNA damage might also constrain leukaemic self-renewal and malignant haematopoiesis. Here we show that the histone methyl-transferase MLL4, a suppressor of B-cell lymphoma 5, 6 , is required for stem-cell activity and an aggressive form of acute myeloid leukaemia harbouring the MLL-AF9 oncogene. Deletion of MLL4 enhances myelopoiesis and myeloid differentiation of leukaemic blasts, which protects mice from death related to acute myeloid leukaemia. MLL4 exerts its function by regulating transcriptional programs associated with the antioxidant response. Addition of reactive oxygen species scavengers or ectopic expression of FOXO3 protects MLL4 2/2 MLL-AF9 cells from DNA damage and inhibits myeloid maturation. Similar to MLL4 deficiency, loss of ATM or BRCA1 sensitizes transformed cells to differentiation, suggesting that myeloid differentiation is promoted by loss of genome integrity. Indeed, we show that restrictionenzyme-induced double-strand breaks are sufficient to induce differentiation of MLL-AF9 blasts, which requires cyclin-dependent kinase inhibitor p21 Cip1 (Cdkn1a) activity. In summary, we have uncovered an unexpected tumour-promoting role of genome guardians in enforcing the oncogene-induced differentiation blockade in acute myeloid leukaemia.
Self-renewal is the hallmark feature both of normal stem cells and cancer stem cells 1 . Since the regenerative capacity of normal haematopoietic stem cells is limited by the accumulation of reactive oxygen species and DNA double-strand breaks [2] [3] [4] , we speculated that DNA damage might also constrain leukaemic self-renewal and malignant haematopoiesis. Here we show that the histone methyl-transferase MLL4, a suppressor of B-cell lymphoma 5, 6 , is required for stem-cell activity and an aggressive form of acute myeloid leukaemia harbouring the MLL-AF9 oncogene. Deletion of MLL4 enhances myelopoiesis and myeloid differentiation of leukaemic blasts, which protects mice from death related to acute myeloid leukaemia. MLL4 exerts its function by regulating transcriptional programs associated with the antioxidant response. Addition of reactive oxygen species scavengers or ectopic expression of FOXO3 protects MLL4 2/2 MLL-AF9 cells from DNA damage and inhibits myeloid maturation. Similar to MLL4 deficiency, loss of ATM or BRCA1 sensitizes transformed cells to differentiation, suggesting that myeloid differentiation is promoted by loss of genome integrity. Indeed, we show that restrictionenzyme-induced double-strand breaks are sufficient to induce differentiation of MLL-AF9 blasts, which requires cyclin-dependent kinase inhibitor p21
Cip1 (Cdkn1a) activity. In summary, we have uncovered an unexpected tumour-promoting role of genome guardians in enforcing the oncogene-induced differentiation blockade in acute myeloid leukaemia.
Leukaemias with MLL translocations account for the majority of acute lymphoblastic leukaemias and acute myeloid leukaemias in infants, and are associated with extremely poor prognosis and response to conventional therapies 7 . MLL1, the founding member of the MLL family of histone methyltransferases, is essential for stem-cell self-renewal 8 . MLL1 fusion genes lack endogenous histone methyltransferase activity but retain MLL-associated DNA binding 7, 9 ; therefore aberrant self-renewal of myeloid progenitors and malignant cell proliferation is thought to require the recruitment of alternative histone methyltransferases to canonical MLL1 target genes 7, 9 . In addition to MLL1, five MLL family members possess H3K4-specific methyltransferase activity. Among these, MLL4 (also known as Kmt2d and orthologous to the human MLL2 gene) has emerged as a major tumour suppressor gene but its mechanism of action and target genes are unknown 5, 6, 10, 11 . To determine the role of the chromatin regulator MLL4 in normal haematopoiesis and MLL1-fusion-induced leukaemogenesis, we deleted MLL4 in stem and progenitor cells by crossing MLL4 f/f mice with transgenic mice expressing interferon-inducible MxCre (Extended Data Fig. 1a-d) .
Total bone-marrow cellularity was equivalent in polyinosinic:polycytidylic acid (polyIC)-treated wild-type MxCre 1 and MLL4 f/f MxCre 1 mice (herein referred to as WT and MLL4 2/2 respectively) (Extended Data Fig. 1e ). However, the number of Lin 2/2 spleens were significantly larger than controls and exhibited extramedullary haematopoiesis (Extended Data Fig. 2e-h ). Thus, loss of MLL4 results in an expansion of HSCs and myeloid cells but reduced lymphopoesis.
We compared the repopulating ability of a CD45.2 congenic test population (WT or MLL4 2/2 unfractionated whole bone marrow) against equal numbers of WT cells marked with the CD45.1 allele to support transplantation into lethally irradiated WT CD45.1 recipients (Extended Data Fig. 3a) . Peripheral blood analysis revealed that the total CD45.2-derived reconstitution was reduced in mice transplanted with MLL4 2/2 population in competitive assays, MLL4 2/2 bone marrow supported transplant reconstitution in non-competitive repopulation assays (Extended Data Fig. 3m-o) . Thus, although MLL4 deficiency allows for haematopoietic homeostasis, the response to competitive repopulation stress is severely compromised.
Despite the fact that MLL4-mutant mice showed an increase in the number of HSCs and LSKs (Extended Data Fig. 1f-h ), we did not detect an increase in the percentage of cycling (S/G2/M phase) cells (Extended Data Fig. 4a, b) . To examine the symmetry of cell divisions during cell cycle, we purified CD150
CD41
2 Flt3 2 LSK cells and cultured them for an in vitro immunophenotypic division assay (Extended Data Fig. 4c ) 12, 13 . After purification, more than 90% of WT and MLL4
2/2
HSCs expressed the receptor tyrosine kinase molecule Tie2, indicative of their quiescent state (Extended Data Fig. 4d ). During asymmetric division, an HSC gives rise to a copy of itself (indicated by Tie2 
CD48
2 ) and to a committed progenitor daughter cell (indicated by Tie2 Fig. 4c ). We found that after an initial cellular division, the frequency of asymmetric divisions was approximately twofold lower in MLL4
2/2 compared with WT, with a concomitant increase in the frequency of symmetric commitment (Fig. 1d) . Thus, loss of MLL4 is associated with a skewing towards symmetric commitment, which has been linked with attenuated self-renewal capacity 12, 13 . Altogether, our data suggest that under homeostatic conditions loss of MLL4 leads to an increase in HSCs. However, when the cells are forced to enter into cycle under conditions of stress, as during the in vivo repopulation or in vitro cell division assay, their stem-cell capacity is impaired.
To understand how MLL4 regulates stem-cell function, we performed global analysis of gene expression changes in LSK cells. This analysis revealed that genes positively regulated by MLL4 were associated with several processes involved in cellular response to stress (Extended Data  Fig. 4e ). Specifically, gene set enrichment analysis (GSEA) indicated significant enrichment of the glutathione detoxification pathway in the MLL4 positively regulated genes (Extended Data Fig. 4f, g ; false discovery rate (FDR) , 0.1), which was confirmed by quantitative real-time reverse-transcription PCR (RT-qPCR) (Extended Data Fig. 4h ). The members of the FoxO transcription factors family FoxO1, 3 and 4 (FoxOs) are also important mediators of HSC resistance to reactive oxygen species (ROS) 4, 14 . Genes that were downregulated in FoxO-deficient LSKs were also significantly enriched among those genes downregulated in the absence of MLL4 (FDR , 0.1, Extended Data Fig. 4i ). Thus, MLL4 deficiency in the HSC compartment deregulated the expression of genes mediating resistance to oxidative stress.
Oxidative stress and DNA damage limit HSC functional capacity [2] [3] [4] . Flow cytometric analysis revealed that MLL4 2/2 LSKs and HSCs (LSK CD34 lo ) exhibited an increase in ROS (Fig. 1e , bottom, and Extended Data Fig. 4j ) and DNA damage, as measured by levels of phosphorylated Kap1 (Fig. 1e, top) , a target of the DNA-damage kinases ATM, ATR and DNA-PKcs. Thus, the loss of HSC reconstitution potential and self-renewal defects in MLL4 2/2 mice are associated with the accumulation of endogenous ROS and DNA damage signalling. Fig. 4c, d for details) . e, LSK and LSK CD34lo cells from WT or MLL4 2/2 mice were stained with an antibody against phosphorylated Kap1 (top) and DCFDA (29,79-dichlorofluorescein diacetate; bottom). (*P , 0.05; **P , 0.01; ***P , 0.005; ****P , 0.0001). 
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Despite their well-established tumour suppressor functions, FoxOs are required for the maintenance of leukaemic initiating cells in a model that mimics acute myeloid leukaemias containing a translocation between MLL1 and AF9 genes 15 . To determine whether MLL4 modifies MLL-AF9 leukaemia, we introduced MLL-AF9 into WT and MLL4
2/2
bone-marrow haematopoietic stem/progenitor cells with a retrovirus marked with green fluorescent protein (GFP) (MLL-AF9-IRES-GFP) 16 (Extended Data Fig. 5a, c) . When injected into sublethally irradiated recipients, WT cells transformed with MLL-AF9 caused leukaemia, with 70% of the animals succumbing by 80 days (Fig. 2a, b and Extended Data Fig. 5d ). In contrast, MLL4-deficient cells transformed with MLL-AF9 failed to cause leukaemia (Fig. 2a) , even when MLL4 was excised after cells transformed with MLL-AF9 were injected into syngeneic recipients (Extended Data Fig. 5b and Fig. 2e, f) ; moreover, unlike non-transformed MLL4 2/2 counterparts (Extended Data Fig. 5e ), MLL-AF9 MLL4
2/2 cells grew ex-vivo more poorly than WT controls (Fig. 2c, g and Extended Data Fig. 5l ), despite no detectable changes in cell death or retroviral infection frequency (Extended Data Fig. 5f, g ). However, MLL4-deficient colonies contained fewer blasts (undifferentiated cells) and the majority of cells presented morphological characteristics associated with myeloid differentiation ( Fig. 5p, q) . We conclude that although inactivating mutations of MLL4 are found in various cancers 5, 6, 10 , MLL4 is essential for MLL-AF9-induced leukaemia.
To identify the molecular mechanisms underlying the requirement of MLL4 in MLL-AF9 leukaemogenesis, we examined MLL4-dependent gene expression alterations in cells transformed with MLL-AF9 (Extended Data Figs 5j and 6a). GSEA revealed a marked downregulation of genes highly expressed in the MLL-AF9 leukaemic stem-cell (LSC) signature in MLL4-deficient cells (FDR , 0.1, Extended Data Fig. 6b) , as well as global upregulation of genes that are downregulated in granulocyte macrophage progenitor-like leukaemic cells (L-GMP) and HSCs relative to committed progenitors (FDR , 0.1, Extended Data Fig. 6c , Methods). Moreover, specific markers of myeloid maturation were significantly upregulated in the absence of MLL4 (FDR , 0.1, fold change . 2) (Extended Data Fig. 6d-f) . Nevertheless, more than 93% of the MLL-AF9 direct targets 17 (including HOXA9 and MEIS1) were not differentially expressed (FDR .0.25, Fig. 3a) , suggesting an alternative mechanism by which the LSC signature and self-renewal are compromised.
Increased levels of ROS in haematopoietic progenitors are associated with myeloid differentiation 4, 18 . On the basis of our finding that MLL4-deficient primary stem cells exhibit higher than normal levels of ROS, we hypothesized that myeloid differentiation of MLL4-deficient MLL-AF9 leukaemia blasts (Fig. 2d, h ) might similarly be a result of dysregulation 
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of antioxidant genes. Consistent with this, the glutathione detoxification pathway and FOXO1/3/4 positively regulated genes were significantly downregulated in MLL4-deficient MLL-AF9 cells (FDR , 0.05, Fig. 3b, c) .
2/2 MLL-AF9 cells exhibited higher levels of ROS than WT cells transformed with MLL-AF9 (Extended Data Fig. 7a ), accompanied by increased levels of phosphorylated Kap-1, chromosomal aberrations and c-H2AX foci (Extended Data Fig. 7b-e) . Thus, MLL4-deficient MLL-AF9 cells have higher than normal levels of ROS and DNA damage.
To test whether ROS was mediating the differentiation of MLL4-deficient MLL-AF9 leukaemic cells, we cultured them with antioxidants N-acetyl-L-cysteine (NAC) and catalase. As expected, MLL4
2/2 MLL-AF9 cells gave rise to significantly fewer colonies than their WT counterparts, but treatment with NAC or catalase partly reversed this phenotype ( Fig. 3d and Extended Data Fig. 7f) , and led to a three-to fivefold increase in the percentage of MLL4-deficient blasts ( Fig. 3e and Extended Data Fig. 7g, h ). This correlated with a decrease in the levels of c-H2AX foci and phosphorylated Kap-1 ( Fig. 3f and Extended Data Fig. 7i, j) . Finally, mice that received MLL4 f/f MxCre 1 MLL-AF9 cells and were fed daily with NAC during and after polyIC administration had reduced survival relative to animals that received the same cells and polyIC treatment but were not treated with NAC (Extended Data Fig. 7k ). Together, these data suggest that protection from oxidative stress and DNA damage by MLL4 is critical to enforce the differentiation blockade and thereby promote the growth of MLL-AF9 leukaemic cells.
Since MLL4 positively regulates FOXO-dependent genes ( Fig. 3c ), we asked whether FOXO3 complementation could bypass the requirement for MLL4. Ectopic FOXO3 expression conferred nearly complete resistance to myeloid differentiation and growth impairment in MLL4 2/2 cells (Extended Data Fig. 7l and Fig. 3 g-i) , and a marked downregulation of MLL-AF9 LSC differentiation signature (Extended Data Fig. 7m ). FOXO3 complementation also reversed many of the transcriptional defects in the glutathione, ROS and FOXO pathways (Fig. 3j) , and levels of ROS were reduced in MLL4 2/2 MLL-AF9 cells overexpressing FOXO3 (Extended Data Fig. 7n ). These results support the notion that the FOXO pathway is a relevant target of MLL4 in protection against ROS.
To determine whether increased oxidative stress was sufficient to confer differentiation of MLL-AF9 leukaemic blasts, we treated WT cells with hydrogen peroxide. This treatment resulted in increased ROS (Extended Data Fig. 8a ), phosphorylated Kap1 (Extended Data Fig. 8b ), myeloid differentiation (Extended Data Fig. 8c ) and a concomitant decrease in the frequency of blasts (Extended Data Fig. 8d, e) . Thus, ROS and DNA-damage signalling are associated with myeloid differentiation.
Since genome stability is a key determinant of the ability of normal HSCs to self-renew and to sustain physiological stress 2, 3, 19 , we hypothesized that tumour suppressors that protect against DNA damage and oxidative stress such as ATM and BRCA1 (refs 20-22) might similarly be required to sustain the differentiation block induced by MLL-AF9. To test this, we measured the growth and morphology of WT, BRCA1 2/2 (BRCA1 f/f 3 Mx-Cre mice treated with polyIC (Extended Data Fig. 8f) ) and ATM 2/2 bone-marrow cells. In granulocyte-macrophage colonyforming unit assays (CFU-GM), loss of ATM and BRCA1 led to a small deficit in cell growth (Extended Data Fig. 8g, h ). When transformed with MLL-AF9, these DNA repair mutants were incapable of maintaining in vitro self-renewal and proliferation without differentiation (Extended Data Fig. 8i-n) . Moreover, treatment of WT MLL-AF9 cells with a specific ATM inhibitor (Ku55933, ATMi) for 48 h led to a 275% increase in their differentiation with negligible cell death (Extended Data  Fig. 8o, p) . Similar results were obtained with a specific ATR inhibitor (Extended Data Fig. 8q ). While deficiencies in either BRCA1 or ATM led to myeloid maturation, loss of ATM was associated with increased levels of DNA damage and ROS (Extended Data Fig. 9a, b) , whereas BRCA1 suppression led to DNA-damage accumulation without a detectable increase in ROS (Extended Data Fig. 9c, d ). We conclude that BRCA1, ATM and ATR are critical for cytoprotective responses that maintain the differentiation blockade induced by the MLL-AF9 oncogene.
To separate the effects of ROS and DNA damage, we generated double-strand breaks (DSBs) directly in WT MLL-AF9 cells with a homing endonuclease I-Ppo1 23 (Extended Data Fig. 10a ). I-Ppo1-infected cells exhibited an increase in levels of Kap-1 phosphorylation but no change in ROS relative to cells infected with empty vector (Fig. 4a, b) . Moreover, upon re-plating we observed fivefold fewer colonies in IPpo1-infected cells (Fig. 4c) , a fivefold reduction in the frequency of blasts (Extended Data Fig. 10b ) and an induction of mature myeloid lineages (Fig. 4d ). To rule out a possible toxic effect of I-Ppo1 interfering with ribosomal biogenesis due to the presence of a recognition site in the 28S ribosomal RNA genes, we used a second inducible restriction enzyme AsiSI (AsiSI-ER-Tet-on) 24 to generate DSBs directly in leukaemic cells (Extended Data Fig. 10c ). Upon co-administration of doxocycline 
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and 4-hydroxytamoxifen (4OHT), AsiSI-ER became expressed and translocated from cytoplasm to nucleus; and c-H2AX was induced in 65% of the cells with no change in the levels of ROS ( Fig. 4e; Extended Data  Fig. 10d) . By 48 h after treatment, there was 60% reduction in the frequency of blasts (Fig. 4f) . Together these data suggest that DSBs either generated indirectly through the production of ROS or produced directly can bypass the MLL-AF9 oncogene-induced differentiation blockade.
Recent studies have uncovered connections between DNA-damage checkpoint pathways, stem-cell self-renewal and differentiation 19, 25 . Since DNA-damage-induced differentiation in MLL-AF9 transformed cells was associated with impaired growth, we wondered whether the cyclindependent kinase inhibitor p21, which regulates the G1-S checkpoint in response to DNA damage, could be involved in terminal differentiation. In contrast to MLL4-, ATM-and BRCA1-deficiency, loss of p21 had no negative impact on proliferation or myeloid differentiation in the setting of MLL-AF9 transformation (Extended Data Fig. 10 e, f) . However, after exogenous DNA damage, p21 transcripts were induced (Extended Data Fig. 10g) . Moreover, when exogenous DSBs were generated either by activation of AsiSI-ER (Fig. 4e-g and Extended Data Fig. 10c, h ) or by ATMi treatment (Fig. 4h, i and Extended Data Fig. 10i ), p21-deficient MLL-AF9 cells were resistant to DNA-damage-induced differentiation and growth inhibition. These data suggest that DNAdamage-induced cell-cycle exit and differentiation of cells transformed with MLL-AF9 are coupled by the activation of p21.
The 'oncogene-induced replication stress' model for cancer development posits that DNA damage induced by oncogenes in pre-cancerous lesions activates ATM and p53, which in turn trigger cell-cycle arrest, senescence and apoptosis 26 . These well-established DNA-damage checkpoints raise the barrier against tumour progression, but at an advanced disease state this barrier is breached by mutations in ATM and p53, which promote genome instability and cancer 26 . In contrast, our results argue that DNA-damage response proteins are activated in response to MLL-fusion oncogenes, but in this case they are required for tumorigenic function (Extended Data Fig. 10j ). In line with this, suppression of the ATR kinase inhibits acute myeloid leukaemia driven by the MLL-ENL oncogene 27 . One potential mechanism by which DNA damage can induce myeloid differentiation is by lengthening the cell cycle. Indeed, recent studies showed that retroviral transduction of p21 in lymphomyeloid progenitors induced cell-cycle lengthening and consequent accumulation of the lineage determining PU.1 transcription factor, which favours macrophage differentiation 28 . Similarly, we hypothesize that when MLL-AF9 oncogene-induced DNA damage in leukaemic cells reaches beyond a certain threshold, p21 is activated, cells exit the cycle and initiate terminal differentiation. As a corollary, DNA repair pathway inhibitors, such as ATMi/ATRi described here (Extended Data  Fig. 8o, q) , may prove to be a promising modality of differentiation therapy for the treatment of MLL-associated leukaemia.
METHODS SUMMARY

MLL4
f/f mice were crossed to Mx1-Cre (The Jackson Laboratory) mice. Deletion of MLL4 was achieved by injecting MLL4 Mx1-Cre mice with 300 mg of polyIC five times every other day. The experiments were performed 3 weeks after the last polyIC injection. Retroviruses were used to infect bone-marrow cells harvested 4 days after administration of fluorouracil (5-FU) (250 mg per kg). After infection, cells were maintained in methylcellulose in the presence of stem cell factor (SCF; 100 ng ml ) and IL6 (10 ng ml
21
) and used for in vitro assays or injected into irradiated recipients.
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METHODS
Mice. MLL4
f/f mice were generated by inserting a loxp-FRT-Neo-FRT cassette 59 to exon 19 and a loxp site 39 of exon 16 to generate the targeting vector. Targeted embryonic stem cells gave germline transmission and the neo cassette was removed by crossing the mice with Flp deleter mice. Cre recombination removed exons [16] [17] [18] [19] and generated a frameshift mutation that resulted in a truncated protein missing the carboxy (C)-terminal ,4,200 amino acids 11 . These animals were maintained in a B6/129 background. BRCA1 f(D11)/f(D11) (NCI mouse repository), B6-Ly5.2/Cr (NCI mouse repository), B6;129S2-Cdkn1a
) (The Jackson Laboratory), Mx1-Cre (The Jackson Laboratory) and ATM 2/2 (provided by A. WynshawBoris) mice have been described. Experiments were performed with 6-to 10-week-old mice. Males and females were equally distributed between different experimental groups. All mice were housed in the Frederick National Laboratory and treated with procedures approved by the National Institutes of Health Animal Care and Use Committee. PolyIC treatment. Three hundred micrograms of polyIC (Sigma Aldrich) was administered by intraperitoneal injection five times every other day. The experiments were performed 3 weeks after the last polyIC injection. Isolation of bone-marrow cells, flow cytometry and HSC isolation. Bone-marrow cells were flushed from the long bones (tibias and femurs) and stained in PBS (Corning Cellgro) supplemented with 2% of inactivated fetal bovine serum (Gemini BioProducts) with the following antibodies from BD Biosciences: B220 FITC, CD11b FITC, PE, APC or APCcy7, CD11C FITC, PE, APC or APC-cy7, CD4 FITC, PE or APC, CD8 FITC, PE or APC, NK1.1 FITC, Ter119 FITC, CD3 FITC (when gates on lineage negative bone-marrow cells were used, FITC-conjugated antibodies were used), c-Kit PE or APC, Flk2 PE, CD45.2 biotin or FITC, CD45.1 APC, IL7R Alexa 647, CD34 APC, CD150 PE. From eBiosciences: Sca-1 PEcy7, AA4.1 bio or PEcy-7, streptavidin APC. From Invitrogen: streptavidin Pacific blue. DAPI was used to exclude dead cells. Flow cytometry was performed on a fluorescence-activated cell sorting (FACS) Calibur, LSRII or LSR Fortessa (BD Biosciences). Long-term repopulation assays. Two hundred sort-purified LSK bone-marrow cells harvested from 6-to 10-week-old mice were mixed with 500,000 congenic whole bone-marrow cells and injected intravenously into lethally irradiated (900 rad) recipients. For whole bone-marrow transplants, bone-marrow cells (4 3 10 6 to 8 3 10 6 ) harvested from 6-to 10-week-old mice were injected intravenously into lethally irradiated (900 rad) recipients. Beginning 4 weeks after transplantation and continuing for 12-19 weeks, blood was obtained from the tail veins of recipient mice, subjected to lysis of red blood cells (ACK lysing buffer, Quality Biological) and stained with antibodies to monitor engraftment. HSC cell division assays. Division patterns of HSCs were determined as previously described 12 . Briefly, single-cell deposition of bone-marrow CD150
Flt3
2 CD34 2 KSL cells from WT or MLL4 2/2 mice (total 90-180 cells per experiment) were cultured in StemSPAN (StemCell Technologies) supplemented with 50 ng ml 21 SCF and 50 ng ml 21 thrombopoietin. Cells were stained with anti-mouse Tie2 antibody, anti-mouse CD48 antibody and DAPI at day 3. Student's t-test was used to determine statistical significance, and statistical significances in division pattern and the disturbance of division pattern were also confirmed by log-linear model and x 2 test (data not shown). HSC and progenitor replating and granulocyte-macrophage colony-forming unit assays. For HSC isolation from whole bone marrow, c-Kit enrichment was performed using CD117 magnetic beads (Miltenyi). Cells were stained with antibodies against lineage (CD3, CD4, CD8, B220, Ter119, Mac1, Gr1 and Il7ra), Sca1, c-Kit, CD34, Flk2, CD150 and PI. HSCs were sorted as PI 
, CD150
1 on a FACS Aria II (Becton, Dickinson) before genomic DNA isolation and PCR quantification of deletion efficiency. For in vitro replating assays, 1,000 myeloid progenitors from WT and MLL4 2/2 mice were FACS sorted from bone marrow, plated in triplicate in MethoCult M3434 (StemCell Technologies), and grown at low (5%) oxygen conditions. After primary quantification, triplicates were pooled and counted. 10,000 cells per well were plated in triplicates for subsequent analysis. All colonies were quantified after 10 days of growth. For granulocytemacrophage colony-forming unit assays, whole bone-marrow cells were plated in MethoCult M3434 (StemCellTechnologies) in the presence of SCF (100 ng ml 21 ), IL3 (10 ng ml 21 ) and IL6 (10 ng ml 21 ) (all from Peprotech). Colonies were scored between days 10 and 12. Intracellular staining of phosphorylated Kap1 and detection of ROS. To detect Kap1-p cells were fixed and permeablized using the BD Cytofix/Cytoperm Kit (BD Biosciences) as described by the manufacturer. Anti Kap1-p (Bethyl) was added to the cells for 1 h at 4 uC followed by the secondary antibody (either mouse-anti-rabbit Alexa Fluor 488 or Pacific Blue (Invitrogen)). To detect ROS, cells were incubated with DCFDA (29,79-dichlorofluorescein diacetate; Invitrogen) or CellROX Deep Red Reagent (Invitrogen) according to the manufacturer's instructions for 30 min at 37 uC followed by flow cytometry.
Immunofluorescence, metaphase analysis and microscopy. For immunofluorescent staining of c-H2AX and AsiSI-ER, the ERa Antibody (sc-543; Santa Cruz; 1/500) and anti-phospho-Histone H2A.X (Ser139) (JBW301 Millipore, 1/5,000) were used. Cells were treated with doxocycline at 1 mg ml 21 and 4OHT at 1 mM for 24 and 4 h respectively, before fixation and processing as described 29 . Cells were harvested for metaphase analysis as described 30 . Imaging of c-H2AX foci was performed using a wide-field epi-fluorescence Zeiss Axio Observer Z1 microscope equipped with a 320 plan apochromatic lens (numerical aperture 0.8), motorized stage and Zeiss AxioCam CCD (charge-coupled device) camera. Images were acquired and processed using Zeiss Zen imaging software with a custom-made algorithm for foci detection and then filtered based on the nucleus area, staining background and cell morphology. For acquisition of May-Grunwald-Giemsa stained cytospin slides, images were collected using Zeiss Zen image acquisition software controlling an AxioObserver Z1 wide-field microscope equipped with a plan-apochromat 363 (numerical aperture 1.4) objective lens and an AxioCam MRc5 colour CCD camera. Plasmids, transformation and culture of murine cells and generation of leukaemias in vivo. The following plasmids were provided by S. Armstrong: MSCV-MLL-AF9-IRES-GFP, MSCV-MLL-AF9-neo, MSCV-Cre-IRES-Tomato Red and MSCV-IRES-Tomato Red. For construction of the AsiSI-ER-Tet-on vector, a fragment containing HA-ER-AsiSI was PCR amplified from pBabe-AsiSI-ER and cloned under the control of TRE3G doxycycline-inducible promoter of pRT3GEPIR; BamHIMluI sites were used to remove GFP-miR-E, then HA-ER-AsiSI was cloned in pRT3GEPIR. pBabe-AsiSI-ER and pRT3GEPIR were gifts from G. Legube and J. Zuber, respectively. AsiSI-ER-Tet-on and FoxO3 (FoxO3-IRES-GFP) retroviruses were generated in 293T cells. Retroviruses were used to infect bone-marrow cells harvested 4 days after administration of 5-FU (250 mg per kg) as previously described 31 .
After infection, cells were maintained in methylcellulose (Methocult, StemCell Technologies) in the presence of SCF (100 ng ml 21 ), IL3 (10 ng ml
21
) and IL6 (10 ng ml 21 ) (all from Peprotech). Eight days after infection, 3 3 10 6 cells were injected intravenously into sublethally irradiated recipients (650 rad). White bloodcell counts were monitored from peripheral blood collections using a Hemavet (Drew Scientific). For all colony assays, MLL-AF9-infected cells were plated at 1,000 or 5,000 cells in Methocult in the presence of IL3, Il6 and SCF as above. When used, NAC (Sigma Aldrich) was added at 1 mM, Catalase (Sigma Aldrich) at 100 mg ml 21 and ATMi KU55933 (TOCRIS Bioscience) at 5 mM. ATRi 32 was used at 1 mM. For in vivo experiments, 5 mg ml 21 of NAC was added to the drinking water. Colony assays and cell morphology staining. For colony assays, cells were plated in M3434 cytokine-enriched methylcellulose (Stem Cell Technologies) according to the manufacturer's instructions. Cytospins were performed in a Shandon Cytospin 4 (Thermo Scientific) and cells were stained first with May-Grünwald dye and then Giemsa stain (both from Sigma Aldrich). For the experiments with MLL-AF9 cells stably infected with AsiSI-ER-Tet-on, AsiSI-ER was induced with doxocycline at 1 mg ml -1 and 4OHT at 1 mM for 24 and 4 h, respectively, in liquid media, then plated in M3434 cytokine-enriched methylcellulose and maintained at the same concentration of doxocycline and 4OHT until the end of the experiment. qPCR. RNA extraction was performed using a QIAGEN RNeasy Mini Kit. Complementary DNA (cDNA) was synthesized from RNA with a Superscript II kit (Invitrogen). Transcripts were amplified with Sybr Green PCR Master Mix (ABI). qPCR was performed on an ABI Prism real-time PCR system. The following primers were used to quantify MLL4 expression: MLL4-F 59-GCCACCTCTTGGCCTGT TCA-39; MLL4-R 59-ACACAACGCCAGCCCTTCAG-39. The following primers were used to quantify Prdx1, Cstb, Txnip and p21 expression: Prdx1-F 59-GCGC TTCTGTGGATTCTCACTTCT-39, Prdx1-R 59-ACTCCATAATCCTGAGCAA TGGTG-39, Cstb-F 59-GAAGTCCCAGCTTGAATCGAAAGAA-39, Cstb-R 59-TAGGAAGACAGGGTCAAAGGCTTGT-39, Txnip-F 59-GCTGCAACATCCT CAAAGTCGAA-39, Txnip-R 59-TCTTGAGAGTCGTCCACATCGTC-39, p21F 59-CTGGGAGGGGACAAGAG-39 and p21 R-59-GCTTGGAGTGATAGAAAT CTG-39. The MLL4 flox and Cre-deleted alleles were quantify using the following primers: MLL4DNA-A 59-AGGAACCTGAGGGAAACGAACC-39, MLL4DNA-B 59-GGAGAACAGGAGATGCCTCAGC-39, MLL4DNA-C 59-TGCAGAAGCC TGCTATGTCCAG-39. shRNA targeting MLL4 expression. TransOMIC shRNAmir against MLL4 (RLGM-GU42557, target sequence: TGGGAATGATTCTAAAATGTT) and non-targeting control shRNA-mir (TRM1103, target sequence: ACCGGCTGAAGAGCCTGA TCA) were cloned from pMLP to the pLEPG backbone (a gift from J. Zuber). Retroviruses were generated in Phoenix-eco cells. WT MLL-AF9 cells were infected and selected for 96 h in puromycin (4 mg ml 21 ), and depletion of MLL4 messenger RNA (mRNA) was measured by qPCR using the primers for MLL4 mRNA described above. RNA-seq. To perform RNA-seq in MLL-AF9-infected cells, RNA extraction was performed using TRIzol (Ambion) following the manufacturer's protocol. RNA was washed, purified with an RNeasy kit (QIAGEN) and measured for quality using Agilent RNA 6000, Nano reagents and Bioanalyzer. RNA was then prepared RESEARCH LETTER for sequencing using a TruSeq RNA sample prep kit (Illumina). To perform RNAseq in LSK cells, we followed a protocol for single cell RNA-seq 33 . Sequence reads from each cDNA library were mapped onto the Build 37 assembly of the National Center for Biotechnology Information mouse genome data (July 2007; NCBI37/ mm9) using TopHat, and outputted to bam format 34 . Bioconductor 35 packages were used to quantify the expression abundance of RefSeq genes from the aligned reads and calculate the reads per million on the genes' exons. For comparison of RNAseq experiments in CRE-infected MLL4 f/f cells transformed with MLL-AF9 versus CRE-infected WT cells transformed with MLL-AF9, genes with more than a twofold change and FDR , 0.1 were designated as MLL4-dependent genes. Visualization was achieved by generating custom tracks for the University of California at Santa Cruz Genome Browser. Gene set analysis. Gene sets were obtained from the biological processes classification from Gene Ontology 36 , Reactome 37 and Pathway Commons 38 to assess the canonical pathways and biological processes over-represented among the genes downregulated in MLL4f/f MxCre (MLL4 2/2 ) versus WT MxCre (WT) LSK cells. MLL-AF9 direct target genes were identified using the MLL-AF9 ChIP-seq data set deposited at the GEO under accession code GSE29130 and compared with MLL4-dependent genes in cells transformed with MLL-AF9. Fisher's exact test with Benjamini-Hochberg multiple-testing correction 39 was used as the measure of gene set over-representation. GSEA used Pre-ranked tool version 2.0.12 with 10,000 permutations. Moderated logarithmic fold change was used as the gene dysregulation ranking metric. MLL-AF9 'leukemic stem cell' self-renewal associated signatures (Up LSC and Down LSC) were defined on the basis of the microarray data set from ref. 16 was used for microarray processing and differential gene expression. The glutathionemediated detoxification pathway is a modified version of the genes annotated for the process at Pathway Commons 38 . The heatmap plot in Fig. 3j was generated on the genes in the glutathione, ROS and FOXO pathways that were associated with MLL4 deficiency identified by the leading edge of GSEA analyses unless indicated otherwise in the plot.
Statistical analyses. Multiple independent biological experiments were performed to assess the reproducibility of experimental findings. Each group is presented by mean 6 s.d. To compare two experimental groups, statistical tests were conducted using R statistical language (http://r-project.org). Unpaired, one-tailed t-tests were used for all analyses. For ex vivo experiments, multiple independent biological replicates were used. For leukaemia transplantation, five to seven recipients per group were used since variation among experiments was low. Animals were placed in different experimental groups and disease development was accessed blindly without prior knowledge of genotype. The significance between the longevity of cohorts was assessed by Kaplan-Meier survival analysis and log-rank (Mantel-Cox) tests. P values less than 0.05 were considered significant to reject the null hypothesis. No randomization was used in any experiment.
Extended Data Figure 1 | Deletion of MLL4 in haematopoietic stem cells. a, MLL4f/f mice (see methods) were crossed with the interferon-inducible transgene MxCre to obtain MLL4f/f MxCre and WTMxCre mice. Animals were then treated with intraperitoneal (ip) injections of 300 mg of polyIC five times every other day and analysed 3 weeks after the last polyIC injection (generating WT and MLL4 2/2 mice). b, The MLL4 wild-type locus (WT) and the floxed exons locus before and after Cre excision. Exons are represented in numbered boxes. The loxP sites (red rectangles) and the MLL4 PCR primers (black arrows) are indicated. c, PCR analysis for conditional MLL4 knockout mice (exons 16, 17, 18, 19) . Genomic DNA from sorted HSCs derived from WT and MLL4 Fig. 3e . Data are shown normalized to WT counts (dotted line) in two independent experiments. h, Frequency of blasts with or without catalase treatment were quantified on the basis of morphology. i, j, NAC or catalase treatment reduces the levels of phosphorylated Kap1 in MLL4-deficient MLL-AF9 cells. The two different treatments (NAC, catalase) and controls (red and black lines) were performed in the same experiment but controls are plotted separately in i and j for simplicity. k, Bone-marrow cells from MLL4 f/f MxCre mice (without polyIC treatment) were collected 4 days after 5-FU treatment and infected with a retrovirus containing MLL-AF9. After expansion in semi-solid media, cells were injected into mice that were subsequently (1 week later) administered polyIC to excise MLL4 in vivo. One group of mice was fed with NAC in the drinking water starting 1 week before the injection of the transformed cells. Two out of five animals treated with NAC died (both animals displayed elevated white blood cell counts at time of death) and none of the untreated mice died (and all had normal white blood cell counts). Survival curves were determined at the indicated time points; n 5 5 mice per group. l-n, MLL4
2/2 bone-marrow cells were co-transformed with MLL-AF9-neo and either empty vector or retroviruses encoding FOXO3-IRES-GFP. One week after selection in G418, GFP 1 cells were sorted, then cultured ex vivo. m, GSEA plot demonstrates that FOXO complementation reversed upregulation of LSC Down gene set in MLL4 Fig. 5a ) and expanded in semi-solid media. Cells were treated with 100 mM H 2 O 2 and the levels of ROS detected by DCF-DA staining (a) and phosphorylated Kap1 (b) were determined 48 h after treatment. One representative of two independent experiments is shown. The number of cells with blast morphology (c) was quantified 48 h after treatment (d). Red stars in (c) indicate cells with morphological changes characteristic of differentiation; images of one out of two independent experiments. The same WT controls were used in Fig. 2d . Bar graph shows mean 6 s.d. of two independent measurements. e, Bar graph shows the frequency of propidium iodide (PI)-positive cells 48 h after 100 mM H 2 O 2 treatment. f, Genomic DNA was extracted from WT and BRCA1 f/f MxCre bone-marrow cells from mice treated or not with polyIC. Detection of the WT-, deleted-and floxed alleles of BRCA1 are indicated. g, h, Whole bone-marrow cells of the indicated genotypes were cultured in methylcellulose media supplemented with IL3, IL6 and SCF and the colony numbers were scored between days 8 and 10. WT or ATM 2/2 cells were transformed with MLL-AF9 as shown in Extended Data Fig. 5a , and blast colony counts (i) and morphology in methylcellulose, May-Grünwald-Giemsa stains (j) were determined 10 days later; images of one out of three experiments. Bar graph shows mean 6 s.d. of four independent experiments. k, The frequency of cells identified as blasts in (j) was determined. Data are shown normalized to WT counts (dotted line) in three independent experiments. l-n, Three weeks after polyIC treatment of WTMxCre and BRCA1 f/f MxCre mice, bone-marrow cells were transformed with MLL-AF9, and blast colony counts (l) and colony morphology (m) were assessed at day 10 after transformation (images of one out of two experiments). Bar graph shows mean 6 s.d. of three independent experiments. n, The frequency of cells identified as blasts is shown normalized to WT counts (dotted line) in two independent experiments. o, WT cells transformed with MLL-AF9 (as in Extended Data Fig. 5a ) were expanded in semi-solid media, treated with 5 mM of ATMi or vehicle for 48 h, and the frequency of blasts and cells at different stages of differentiation was determined by morphology. p, Cells transformed with MLL-AF9 were treated with 5 mM of ATMi for 48 h, and the frequency of propidium iodide (PI)-positive cells is plotted. q, Cells transformed with MLL-AF9 were treated with 1 mM of ATRi for 24-48 h and the frequency of blasts was determined. One of two representative experiments is shown. Scale bars, 10 mm. LETTER RESEARCH
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